Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1940-0640
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs ; volume:16 ; number:1 ; day:24 ; month:10 ; year:2021 ; pages:1-10 ; date:12.2021
Addiction science & clinical practice ; 16, Heft 1 (24.10.2021), 1-10, 12.2021
- Creator
-
Scott, Travis M.
Arnsten, Julia
Olsen, James Patrick
Arias, Franchesca
Cunningham, Chinazo O.
Rivera Mindt, Monica
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13722-021-00272-4
- URN
-
urn:nbn:de:101:1-2022010418533694707631
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Scott, Travis M.
- Arnsten, Julia
- Olsen, James Patrick
- Arias, Franchesca
- Cunningham, Chinazo O.
- Rivera Mindt, Monica
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats
Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
Healthcare provider perspectives on emergency department-initiated buprenorphine/naloxone: a qualitative study
Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report
Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
The barriers to smoking cessation in Swiss methadone and buprenorphine-maintained patients
The use of buprenorphine/naloxone to treat borderline personality disorder: a case report
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats
Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
Healthcare provider perspectives on emergency department-initiated buprenorphine/naloxone: a qualitative study
Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report
Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
The barriers to smoking cessation in Swiss methadone and buprenorphine-maintained patients
The use of buprenorphine/naloxone to treat borderline personality disorder: a case report
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats
Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
Healthcare provider perspectives on emergency department-initiated buprenorphine/naloxone: a qualitative study
Buprenorphine/naloxone – one formulation that doesn’t fit all: a case report
Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
The barriers to smoking cessation in Swiss methadone and buprenorphine-maintained patients